Results 161 to 170 of about 5,730 (206)
Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil. [PDF]
Rev Soc Bras Med TropHyppolito EB +18 more
europepmc +1 more source
Computational repurposing of polyphenols for anti-Mpoxviral activity. [PDF]
In Silico PharmacolAstakala RV +6 more
europepmc +1 more source
HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation. [PDF]
Drug Metab DisposWork HM, Hackett JC, Lampe JN.
europepmc +1 more source
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen [PDF]
Antimicrobial Agents and Chemotherapy, 2017 Interactions between simeprevir (hepatitis C virus [HCV] NS3/4A protease inhibitor) and ledipasvir (HCV NS5A replication complex inhibitor) were investigated in treatment-naive HCV genotype 1-infected patients without cirrhosis, treated with simeprevir ...
Yves Horsmans +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Simeprevir: First Global Approval
Drugs, 2013Simeprevir (Sovriad(TM)) is a new direct-acting antiviral drug and a second-generation small-molecule NS3/4A serine protease inhibitor developed by Janssen and Medivir for the oral treatment of adults with genotype 1 and/or genotype 4 chronic hepatitis C virus (HCV) infection (chronic hepatitis C).
Asha, Vaidya, Caroline M, Perry
openaire +2 more sources